Eyenovia Stock Set to Reverse Split on Monday, February 3rd (NASDAQ:EYEN)

Shares of Eyenovia, Inc. (NASDAQ:EYEN) are set to reverse split on the morning of Monday, February 3rd. The 1-80 reverse split was announced on Tuesday, January 28th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 31st.

Eyenovia Stock Performance

Shares of EYEN opened at $0.04 on Thursday. Eyenovia has a 12-month low of $0.04 and a 12-month high of $2.57. The stock has a market cap of $4.15 million, a P/E ratio of -0.05 and a beta of 1.31. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The company has a 50-day moving average of $0.09 and a two-hundred day moving average of $0.46.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the previous year, the business posted ($0.18) earnings per share. As a group, research analysts predict that Eyenovia will post -0.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on EYEN. William Blair reiterated a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th. HC Wainwright lowered shares of Eyenovia from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $12.00 to $2.00 in a report on Monday, November 18th. Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. Finally, LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th.

Hedge Funds Weigh In On Eyenovia

A number of hedge funds have recently made changes to their positions in EYEN. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eyenovia during the second quarter valued at approximately $26,000. Financial Management Network Inc. acquired a new stake in Eyenovia during the 3rd quarter valued at $39,000. Nations Financial Group Inc. IA ADV increased its stake in Eyenovia by 78.6% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock worth $47,000 after buying an additional 40,000 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Eyenovia by 36.6% in the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after buying an additional 149,471 shares in the last quarter. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.